CROP Announces Addition of Former Coca-Cola Branding Exec Arashdeep Singh to Head Up CannaDrink Line
Momentum Public Relations
Press Release: October 31, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today it has signed former Coca-Cola branding executive Arashdeep Singh to lead the CannaDrink beverage line.
Singh has nearly a decade of experience with The Coca-Cola Company, including his last position as a Senior Brand Manager for a C$750.0 million portfolio of Coca Cola trademark products. His experience includes a varied mix of marketing disciplines and is a specialist in brand marketing and new product launches.
Over the years with Coca-Cola, Singh:
- Drove integrated brand campaigns to add new consumers and drive consumption frequency, using a combination of digital and traditional media.
- Built a new consumption occasion using a strong festival campaign for deeper household penetration.
- Led the creative agencies to conceptualize and execute integrated brand campaigns and build key brand imagery statements.
- Helped launch Coca-Cola Zero in the markets of Bhutan & Sri Lanka to develop the Diets & Lights category.
- Recruited new consumers by inducing more trials for the brand using experiential sampling. Added to key brand pillars of Brand Preference and Brand Love Score.
- Partnered with the National Customers and Emerging channels to drive volume growth
Standardized the E-Commerce presence with new layouts from a commissioned research to drive click-through rates. - Contributed to household penetration using innovative point of sale interventions in Modern trade. Arrested decline in Cinemas using co-branded incidence drivers with key customers.
CROP CEO, Michael Yorke, stated: “Someone of Arash’s caliber joining us is a big boost for our management team. As a growing organization our executive branch often wears many hats so having a specialist like Arash to head up this important pillar of CROP’s growth is exciting for myself and the entire CROP family.”
Arashdeep Singh, Head of Marketing at CannaDrink said, “For years, the benefits of cannabidiol have languished under a false stigma. With a welcome expansion of legalization, CannaDrink is committed to bring these products to the new age consumers. I am truly excited to be a part of this evolutionary journey.”
About CROP
Crop is publicly listed on the CSE and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is focused on cannabis branding and real estate assets. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Business, CROP Infrastructure, Marijuana, Medical Marijuana, News Home
CROP Announces Addition of Former Coca-Cola Branding Exec Arashdeep Singh to Head Up CannaDrink Line
Momentum Public Relations
Press Release: October 31, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today it has signed former Coca-Cola branding executive Arashdeep Singh to lead the CannaDrink beverage line.
Singh has nearly a decade of experience with The Coca-Cola Company, including his last position as a Senior Brand Manager for a C$750.0 million portfolio of Coca Cola trademark products. His experience includes a varied mix of marketing disciplines and is a specialist in brand marketing and new product launches.
Over the years with Coca-Cola, Singh:
- Drove integrated brand campaigns to add new consumers and drive consumption frequency, using a combination of digital and traditional media.
- Built a new consumption occasion using a strong festival campaign for deeper household penetration.
- Led the creative agencies to conceptualize and execute integrated brand campaigns and build key brand imagery statements.
- Helped launch Coca-Cola Zero in the markets of Bhutan & Sri Lanka to develop the Diets & Lights category.
- Recruited new consumers by inducing more trials for the brand using experiential sampling. Added to key brand pillars of Brand Preference and Brand Love Score.
- Partnered with the National Customers and Emerging channels to drive volume growth
Standardized the E-Commerce presence with new layouts from a commissioned research to drive click-through rates. - Contributed to household penetration using innovative point of sale interventions in Modern trade. Arrested decline in Cinemas using co-branded incidence drivers with key customers.
CROP CEO, Michael Yorke, stated: “Someone of Arash’s caliber joining us is a big boost for our management team. As a growing organization our executive branch often wears many hats so having a specialist like Arash to head up this important pillar of CROP’s growth is exciting for myself and the entire CROP family.”
Arashdeep Singh, Head of Marketing at CannaDrink said, “For years, the benefits of cannabidiol have languished under a false stigma. With a welcome expansion of legalization, CannaDrink is committed to bring these products to the new age consumers. I am truly excited to be a part of this evolutionary journey.”
About CROP
Crop is publicly listed on the CSE and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is focused on cannabis branding and real estate assets. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Business, CROP Infrastructure, Marijuana, Medical Marijuana, News Home
CROP’s Washington ‘The Park’ Begins Harvesting
Momentum Public Relations
Press Release: October 24, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today that its tenant has begun harvesting at the greenhouse complex known as ‘The Park’, situated in Wheeler Park, Washington State.
The Park’s 35,000 square foot cannabis greenhouse recently underwent a complete retrofit for hydroponic automation and the addition of 500 Gavita HPS grow lights. It has five flowering bays and is sited on nine acres with full scale production estimated at approximately 12,000 pounds of high-quality cannabis annually (about 1,000 pounds per month). The operating costs are about $50,000 (U.S.) per month.
CROP CEO, Michael Yorke, stated: “CROP now has tenant harvests underway in two states, Washington and Nevada. Inventories are accumulating in California, and tenants are accepting bids from potential distributors and buyers to be sold under CROP Brands. Production levels are on target as are costs and we look forward to a strong finish to the year.”
About CROP
Crop Infrastructure Corp. is publicly listed on the Canadian Securities Exchange and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is primarily engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, a 1,865 acre CBD farm, extraction in Nevada with international focuses in Jamaica and Italy and a joint venture on West Hollywood and San Bernardino dispensary applications.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Business, CROP Infrastructure, Marijuana, News Home
Canada Cobalt Discovers Broad New Mineralized Zones in Drilling 1.5 km East Of Castle Mine
Momentum Public Relations
Press Release: October 24, 2018
Cobalt Works Inc. (TSXV: CCW) (OTC: CCWOF) (Frankfurt: 4T9B) (the “Company” or “Canada Cobalt”) is pleased to announce that drilling 1.5 km east-southeast of the Castle mine, in an under-explored area prospective for a new deposit type, has intersected well-mineralized felsic Archean units at a downhole depth between 77 meters and 163 meters as well as mineralized mafic to ultramafic units above and below over significant widths starting from surface.
Drilling of this third hole of the program continues.
The upper 77 meters of the hole is a coarse-grained, variable-textured and apparent cumulate gabbroic body (crystals up to 1 cm diameter) with disseminated pyrite throughout. From 77 m to 163 m is an intensely-altered, silicified and pyritized zone of felsic rocks unlike anything previously intersected at the Castle Property. Below the highly silicified unit are mineralized mafic to ultramafic units. Mineralization in these units consists of four distinct horizons featuring up to 1-cm diameter, coarse-grained blebby sulphides.
Core is being investigated and assayed for gold, platinum group elements, nickel and other potential metals.
A thin layer of overlying Huronian sedimentary rocks masked this area from previous exploration. The hole, collared 27 meters south of a strong, multi-element MMI soil anomaly and at the center of a 725-meter-long east-west trending IP anomaly with an associated chargeability halo, was drilled toward the north.
At the completion of this hole, a follow-up hole will be collared to the north of the MMI anomaly and 50 meters to the west, drilled southward to give a second cut through these newly-discovered mineralized zones.
Underground Drilling Update
A total of 67 underground drill holes have now been completed on the first level of the Castle mine. Visual analysis of core supports the Company’s geological model that many well-mineralized cobalt vein structures were left behind by previous operators. The Company looks forward to providing initial assay results, and a steady stream thereafter, within the next seven to 10 days.
Pilot Plant Produces 8.25% Cobalt Concentrate From Waste Pile
Canada Cobalt’s on-site proprietary pilot plant recently produced a gravity concentrate from a 250-kilogram sample randomly selected from the Castle mine waste pile (material left behind outside the mine by previous operators). Subsequent assaying by Swastika Laboratories has returned a cobalt concentrate grading 8.25%, featuring head grades of 0.39% cobalt and 1,905 g/t silver.
Frank Basa, Canada Cobalt President and CEO, commented, “Such head grades from the waste pile at Castle are extremely encouraging, not to mention our ability to produce such a high cobalt concentrate on site from material that was considered waste decades ago. Our proprietary Re-2OX process takes the concentrate from this stage, removes the arsenic and converts the concentrate into a client-specific technical grade cobalt sulphate.”
Quality Assurance/Quality Control
Two samples weighing a total of 250 kilograms, having been processed in Canada Cobalt Works’ proprietary Re-2OX pilot plant at the Castle Property, were taken to Swastika Laboratories in Swastika, Ontario, for analysis where a pulp-metallic analysis was completed for the silver assays. The entire sample was dried, weighed and crushed over 95%, then fully pulverized and passed through 147-micron screen to create a plus 147-micron fraction (metallics) and a minus 147-micron fraction (pulp). Approximately 50 grams of the metallic fraction was weighed, fused and assayed by fire assay. The resulting dore bead of gold and silver was weighed before adding HNO3 acid to dissolve the silver. The remaining gold bead was weighed and subtracted from the gold + silver bead to give a silver weight and grade for the metallics portion. The minus-147 fraction (pulp) had 2 samples from entire pulp which were weighed and then digested by two acid aqua regia and finalized by AAS reading for Co, Ag and Ni. Final silver grade is a calculated weighted average using grades and weights from both pulps and metallics. As gold was not assayed in the pulps, the final gold assay was calculated by weighted average, as for the silver, but assuming a 0.0 g/t Au grade for the pulp portion. Cobalt, nickel and copper were provided as percent grade. Analytical accuracy and precision are monitored by the analysis of reagent blanks and reference materials at the lab.
Qualified Person
The technical information in this news release was prepared under the supervision of Frank J. Basa, P.Eng., Canada Cobalt’s President and Chief Executive Officer, who is a member of Professional Engineers Ontario and a qualified person in accordance with National Instrument 43-101.
About Canada Cobalt Works Inc.
Canada Cobalt is a pure play cobalt company focused on its past producing Castle mine in the Northern Ontario Cobalt Camp, Canada’s most prolific cobalt district. With underground access at Castle, a recently installed pilot plant to produce cobalt-rich gravity concentrates on site, and a proprietary hydrometallurgical process known as Re-2OX for the creation of technical grade cobalt sulphate as well as nickel-manganese-cobalt (NMC) formulations, Canada Cobalt is strategically positioned to become a vertically integrated North American leader in cobalt extraction and recovery.
“Frank J. Basa”
Frank J. Basa, P. Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
SOURCE Canada Cobalt Works Inc.
View original content: http://www.newswire.ca/en/releases/archive/October2018/24/c5946.html
Contact:
Frank J. Basa, P.Eng., President and CEO, 1-819-797-4144, or Wayne Cheveldayoff, Corporate Communications, waynecheveldayoff@gmail.com, 1-416-710-2410
- Published in Canada Cobalt Works, Mining, News Home
DIAGNOS Announces Private Placement of Common Stocks and Shares for Debt
Momentum Public Relations
Press Release: October 24, 2018
DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces a private placement (“Private Placement”) of up to 8,000,000 units (each a “Unit”) issued at $0.05 per Unit for gross proceeds of up to $400,000. The Corporation also announces its intention to issue 4,375,000 common shares in payment for a debt of $218,750 related to interests payable on outstanding convertible debentures and convertible notes.
Private Placement
Each Unit consists of;
(i) | one common share (“Share”), and |
(ii) | one stock warrant (“Warrant”) entitling the holder to purchase one Share per Warrant at a price of $0.07 per Share, for a period of 18 months from the date of issuance of the Warrant. |
The proceeds will be used mainly to fund sales and marketing as well as administrative expenses.
One participant in the Private Placement is a director of DIAGNOS and, therefore, considered a “related party” of the Corporation within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The director is expected to subscribe for up to 2,000,000 Units and, together with one related person, would exercise, as a result of the Private Placement, control over 5.15% of the common shares of DIAGNOS. The transaction is exempt from the valuation requirement and the minority approval requirement prescribed in MI 61-101 based on the fact that the fair market value of the related party’s participation in the Private Placement does not exceed 25% of DIAGNOS’ market capitalization prior to the closing of the Private Placement.
Shares issued as part of the Private Placement as well as the underlying Shares to be issued upon exercise of the Warrants are subject to a statutory four-month hold period from the date of issuance.
Closing of the Private Placement is scheduled for October 30, 2018. The Private Placement is subject to receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the execution of formal documentation.
Shares for debt
The Corporation intends to issue 4,375,000 common shares at a deemed price of $0.05 in payment for a debt of $218,750 related to interests payable on outstanding convertible debentures and convertible notes.
Satisfying this outstanding indebtedness with shares was undertaken in order to preserve the Corporation’s cash for operational purposes.
One participant eligible to receive common shares as part of the shares for debt arrangement is a director of DIAGNOS and, therefore, considered a “related party” of the Corporation within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The director, together with one related person, is expected to receive 230,000 common shares. The transaction is exempt from the valuation requirement and the minority approval requirement prescribed in MI 61-101 based on the fact that the fair market value of the related party’s participation in the shares for debt arrangement does not exceed 25% of DIAGNOS’ market capitalization. Shares issued to the director and one certain related person, as part of the shares for debt arrangement, are subject to a statutory four-month hold period from the date of issuance.
The issuance of shares as part of the shares for debt transaction is subject to receipt of approvals from all of the parties, as well as from the applicable regulatory authorities, including the approval of the TSX Venture Exchange, and the execution of formal documentation.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com.
- Published in Business, Diagnos, Life Sciences, News Home, Technology
Tetra Bio-Pharma Appoints Richard Giguère Chief Executive Officer of Tetra Natural Health
Momentum Public Relations
Press Release: October 24, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the appointment of Richard Giguère to the position of Chief Executive Officer of Tetra Natural Health Inc. a newly created, wholly owned subsidiary of Tetra Bio-Pharma Inc.
Mr. Giguère has more than 20 years’ experience in national sales and marketing in the pharmaceutical industry. During his career, he has held numerous business development, management and negotiation positions and launched several new products on the Canadian market. He has worked for several pharmaceutical companies in sectors such as generics, branded products and medical devices. He has also worked with OTC, natural products and original medications. Richard is recognized for his deep ethical sense, respect of others and talent for developing long-term business relationships. Over the past 10 years, he served as a member of the Board of Directors of the companies for which he worked.
“Richard has demonstrated his ability as a company builder which will prove crucial in his role as Chief Executive Officer of Tetra Natural Health,” stated Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma Inc. “He has begun preparing Tetra Natural Health as a wholly owned subsidiary of Tetra Bio-Pharma with the intentions of creating a market leader in the wellness sector of the cannabis market.”
“I am honored by this appointment as well by the confidence that Tetra Bio-Pharma has shown in me,” said Richard Giguère, CEO of Tetra Natural Health Inc. “As the CEO of Tetra Natural Health, I am excited and deeply committed to lead the operations of Tetra Natural Health with my colleagues through the next stages of development and success. Tetra has a sound business model, and there are several significant opportunities for Tetra Natural Health to grow and commercialize innovative natural health products. I am committed to exploiting the development of this huge potential market in the natural health sector.”
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Arctic Star Announces Management Changes
Momentum Public Relations
Press Release: October 23, 2018
Arctic Star Exploration Corp. (TSXV: ADD) (“Arctic Star” or the “Company”) is pleased to report that Executive Chairman and Director Patrick Power, has been appointed as President and Chief Executive Officer. Scott Eldridge has resigned as President and Chief Executive Officer, and will remain with Arctic Star as a Director. In the new corporate structure, effective immediately, Mr. Power will assume all operational duties.
Patrick Power is a seasoned venture capitalist and financier with over 20 years of experience as a stock market professional and as director of public companies. Arctic Star benefits from Mr. Power’s wealth of experience as a savvy deal maker, an adept financier and as a results-driven leader of dynamic public companies. The company enjoys Mr. Power’s large network of contacts within the industry.
About Arctic Star
The Company owns 100% of the recently acquired Timantti Diamond Project including a 243 Ha Exploration Permit and a 193,700 Ha Exploration Reservation near the town of Kuusamo, in Finland. The project is located approximately 550km SW of the operating Grib Diamond Mine in Russia. Arctic has commenced its exploration in Finland on the Timantti Project, where four diamondiferous kimberlite bodies may represent the first finds in a large kimberlite field. The Company also controls diamond exploration properties in Nunavut (Stein), the NWT (Diagras and Redemption) and a rare metals project in BC (Cap). Arctic Star has a highly experienced diamond exploration team previously responsible for several world class diamond discoveries.
ON BEHALF OF THE BOARD OF DIRECTORS OF ARCTIC STAR EXPLORATION CORP.
Patrick Power, Chief Executive Officer
ppower@arcticstar.ca
+1 (604) 218-8772
- Published in Arctic Star Exploration, Mining, News Home
MedX Health adds Stockfleth to medical advisory board
Momentum Public Relations
Press Release: October 23, 2018
MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today that Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany has agreed to join MedX’s Medical Advisory Board. Dr. Stockfleth was previously the Director of the Skin Cancer Center in Berlin.
“The addition of Dr. Stockfleth to our Medical Advisory Board completes our group of highly accomplished physicians from around the world. They are respected thought leaders located in our targeted markets. We are very fortunate to have access to Dr. Stockfleth’s knowledge and expertise,” said Scott Spearn, CEO of MedX.
“MedX’s non-invasive skin cancer scanning technology is ground-breaking and I am honored to be a member of such an esteemed group of physicians,” Dr. Stockfleth said. “I see first-hand how MedX’s technology is a game-changer in early detection of skin cancers,” he added. He noted that his clinic in Bochum receives in excess of 800 calls per day with respect to dermatological issues and has a capacity to handle only about half of the inquiries.
Dr. Stockfleth’s research on dermatology, oncology and in particular, skin cancer, has been extensively published in peer-reviewed journals. He has contributed to the Journal of Infectious Diseases, International Journal of Cancer, Journal of Investigative Dermatology and The Lancet. He is also the former European President of Skin Care in Organ Transplant Patients Network (SCOPE). In 2008 he was one of the founders of the European Skin Cancer Foundation, which assists in developing and providing standardized treatments on a European level. Dr. Stockfleth graduated from the University of Hamburg and is a Jung-Foundation scholar.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181023006008/en/
Contacts:
MedX Health Corp
Scott Spearn, 905-670-4428 ext 229
President and CEO
or
Media Relations
Deborah Thompson, 416-918-9551
dthompson@medxhealth.com
- Published in Business, Life Sciences, MedX Health Corp., News Home, Technology